Evidence map›Paper›PMID 32655558›Full record

ReviewFrontiers in immunology2020

The Human Immune Response to Cadaveric and Living Donor Liver Allografts.

Angus Hann, Daniel-Clement Osei-Bordom, Desley A H Neil, Vincenzo Ronca, Suz Warner, M Thamara P R Perera

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Meta-analysis and meta-regression of outcomes for adult living donor liver transplantation versus deceased donor liver transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Outcome of split liver transplantationWorld journal of gastrointestinal surgery · 2023
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Angus HannThe Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.
Daniel-Clement Osei-BordomInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Desley A H NeilInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Vincenzo RoncaInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Suz WarnerInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
M Thamara P R PereraThe Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.
Queen Elizabeth Hospital Birmingham · GBUniversity of Birmingham · GBBirmingham Children's Hospital · GBUniversity Hospitals Birmingham NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The liver is an important contributor to the human immune system and it plays a pivotal role in the creation of both immunoreactive and tolerogenic conditions. Liver transplantation provides the best chance of survival for both children and adults with liver failure or cancer. With current demand exceeding the number of transplantable livers from donors following brain death, improved knowledge, technical advances and the desire to prevent avoidable deaths has led to the transplantation of organs from living, ABO incompatible (ABOi), cardiac death donors and machine based organ preservation with acceptable results. The liver graft is the most well-tolerated, from an immunological perspective, of all solid organ transplants. Evidence suggests successful cessation of immunosuppression is possible in ~20-40% of liver transplant recipients without immune mediated graft injury, a state known as "operational tolerance." An immunosuppression free future following liver transplantation is an ambitious but perhaps not unachievable goal. The initial immune response following transplantation is a sterile inflammatory process mediated by the innate system and the mechanisms relate to the preservation-reperfusion process. The severity of this injury is influenced by graft factors and can have significant consequences. There are minimal experimental studies that delineate the differences in the adaptive immune response to the various forms of liver allograft. Apart from ABOi transplants, antibody mediated hyperacute rejection is rare following liver transplant. T-cell mediated rejection is common following liver transplantation and its incidence does not differ between living or deceased donor grafts. Transplantation in the first year of life results in a higher rate of operational tolerance, possibly due to a bias toward Th2 cytokines (IL4, IL10) during this period. This review further describes the current understanding of the immunological response toward liver allografts and highlight the areas of this topic yet to be fully understood.

Indexed as

CadaverImmunityLiver TransplantationLiving DonorsTransplantation ImmunologyABO Blood-Group SystemAge FactorsDisease ManagementGraft RejectionGraft SurvivalHumansLiverLiver Function TestsOutcome Assessment, Health CarePractice Patterns, Physicians'Reperfusion InjuryABO Blood-Group Systemcadavericimmunityliverliving donorrejectiontolerancetransplant

Identifiers

PMID32655558
PMCPMC7323572
OpenAlexW3035937355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.